➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Baxter
Dow
AstraZeneca
Johnson and Johnson

Last Updated: March 3, 2021

DrugPatentWatch Database Preview

Gonadotropin, chorionic - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for gonadotropin, chorionic

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Al-Azhar UniversityN/A
Beijing Cancer HospitalPhase 2
3MPhase 1/Phase 2

See all gonadotropin, chorionic clinical trials

Recent Litigation for gonadotropin, chorionic

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Ravgen, Inc. v. Progenity, Inc.2020-12-20
Par Pharmaceutical, Inc. v. Amneal Pharmaceuticals of New York, LLC2018-12-19
Amgen Inc. v. Accord Healthcare, Inc.2018-06-28

See all gonadotropin, chorionic litigation

PTAB Litigation
PetitionerDate
Quest Diagnostics Incorporated2020-09-11
2017-01-10
2013-07-29

See all gonadotropin, chorionic litigation

Patent Text Search: US Patents for gonadotropin, chorionic

These patents were identified by searching patent claims

Supplementary Protection Certificates for gonadotropin, chorionic

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2010 Austria   Start Trial PRODUCT NAME: CORIFOLLITROPIN ALFA; REGISTRATION NO/DATE: EU/1/09/609/001-002 20100125
2017 00022 Denmark   Start Trial PRODUCT NAME: REKOMBINANT FSH (RFSH) INKLUDERENDE ALPHA2,3-SIALYLERING OG ALPHA2,6-SIALYLERING HVOR 80% ELLER MERE AF DEN TOTALE SIALYLERING ER ALPHA2,3-SIALYLERING OG HVOR FRA 5% TIL 20% AF DEN TOTALE SIALYLERING ER ALPHA2,6-SIALYLERING, SAERLIGT FOLLITROPIN DELTA; REG. NO/DATE: EU/1/16/1150/001-003 20161214
C/GB01/022 United Kingdom   Start Trial PRODUCT NAME: RECOMBINANT HUMAN LUTEINISING HORMONE; REGISTERED: UK EU/1/00/155/001-006 20001129
2010000006 Germany   Start Trial PRODUCT NAME: CORIFOLLITROPIN ALFA; REGISTRATION NO/DATE: EU/1/09/609/001-002 20100125
90023-4 Sweden   Start Trial PERIOD OF VALIDITY (FROM - UNTIL): 20290417 - 20311213
2017018 Lithuania   Start Trial PRODUCT NAME: REKOMBINANTINIS FSH, ISKAITANT ALFA 2,3-SIALINIMA IR ALFA 2,6-SIALINIMA, KUR 80 PROCENTU ARBA DAUGIAU BENDRO SIALINIMO YRA ALFA 2,3-SIALINIMAS IR KUR NUO 5 IKI 20 PROCENTU BENDRO SIALINIMO YRA ALFA 2,6-SIALINIMAS, YPATINGAI FOLITROPINAS DELTA; REGISTRATION NO/DATE: EU/1/16/1150 20161212
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Mallinckrodt
AstraZeneca
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.